Compare Icl Group Ltd (ICL) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Philip Morris International Inc. — how do they compare? Icl Group Ltd trades at $5.01 (market cap $6.47B), while Philip Morris International Inc. trades at $200.2 (market cap $312.50B). The key difference: Philip Morris International Inc. is far larger — about 48.3× Icl Group Ltd's market cap, and Icl Group Ltd pays the higher dividend (4.11%). Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Philip Morris International Inc. for 85 Days on average.
| ICL | PM | |
|---|---|---|
Market Cap | $6.47B | $312.50B |
Volume | 1,387,140 | 5,517,172 |
Sector | Basic Materials | Consumer Staples |
52-Week High | $6.84 | $200.50 |
52-Week Low | $4.80 | $144.33 |
Typical Hold Time | 56 Days | 85 Days |
Enterprise Value | $9.11B | $355.62B |
Dividend Yield | 4.11% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.08 with no daily change, showing stable but muted short-term performance. The stock exhibits bearish technical signals with declining revenue and net income margins over recent years, though Q2 2026 earnings beat expectations. Analyst consensus is entirely neutral with 4 hold ratings and a $6.08 price target, suggesting limited near-term upside. Recent news highlights dividend stability and cost-transformation initiatives amid fertilizer industry headwinds.
ICL faces mixed prospects with stable cash flows and dividend payments offset by profitability pressures. The 19.7% upside to consensus target offers moderate potential, but investors must weigh declining margins against operational efficiency efforts. Key risks include input cost inflation and reduced fertilizer demand, requiring careful monitoring of Q3 2026 results and cost program execution.
Philip Morris International (PM) trades at $200.5, up 5.3% over 24 hours, with a bullish technical signal and strong earnings beats in Q1 and Q2 2026. The company shows robust fundamentals with 2025 revenue of $40.65B and net income of $11.35B, supported by a 67.48% gross margin. Recent news highlights expansion of smoke-free products like ZYN and IQOS, now over 40% of revenue, driving growth amid industry shifts.
Outlook is positive with analyst consensus at Buy (68%) and a $212.17 price target, though elevated P/E of 26.46 and regulatory risks in tobacco remain concerns. Earnings growth and smoke-free product adoption are key catalysts, but investors should monitor debt levels and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
